Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA approves lirafugratinib for previously treated, unresectable, locally advanced or ...

23 September 2026 · By · Wire by Fusion42

Published

23 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fda.gov →

◆ Verified

Fusion42 · 23 September 2026 · Fusion42 review

The FDA has approved lirafugratinib for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma, providing a new therapeutic option in this difficult-to-treat cancer.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.

◆ ◆ The Wire takeaway

You now have a new approved drug class to address cholangiocarcinoma patients who have failed prior treatment, making it crucial to adapt your clinical and commercial strategies this quarter.

◆ Coverage

10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026

◆ Topics

BiotechFDA-approvalcholangiocarcinomalirafugratiniboncologydrug-approval